Ixazomib
Ixazomib is a drug used to treat Multiple Myeloma, Lymphoma, Advanced Solid Tumors, and other conditions. Ixazomib is being actively studied in 43 studies and prior, has been studied in 26.
| Top Sponsors | Top Sites | Top Investigators |
|---|---|---|
| Millennium Pharmaceuticals, Inc. | Dana Farber Cancer Institute | Ajai Chari |
| Takeda | Memorial Sloan Kettering Cancer Center | Ajay Nooka |
| M.D. Anderson Cancer Center | Mayo Clinic | Andrew Yee, MD |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
H
Recruiting
- Mantle Cell Lymphoma
- Ixazomib
- Busan, Western, Korea, Republic ofKosin University Gospel Hospital
2022-03-31
Mar 31, 2022D
Active, not recruiting
- Smoldering Multiple Myeloma
- Ixazomib
- +2 more
- Boston, MassachusettsDana Farber Cancer Institute
2022-03-15
Mar 15, 2022M
Active, not recruiting
- Solid Tumors
- Ixazomib
- Erlotinib
- Houston, TexasUniversity of Texas MD Anderson Cancer Center
2022-02-09
Feb 9, 2022P
Recruiting
- Multiple Myeloma
- Multiple Myeloma in Relapse
- Ixazomib
- +2 more
- Boston, MassachusettsDana Farber Cancer Institute
2022-02-28
Feb 28, 2022E
Completed
- Glioblastoma
- Ixazomib
- Atlanta, GeorgiaEmory University/Winship Cancer Institute
2021-03-02
Mar 2, 2021E
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Dexamethasone
- +2 more
- Atlanta, Georgia
- +3 more
2022-01-05
Jan 5, 2022T
Not yet recruiting
- Multiple Myeloma
- Ixazomib
- +3 more
- (no location specified)
2021-12-20
Dec 20, 2021E
Active, not recruiting
- Mantle Cell Lymphoma
- Ixazomib
- Rituximab
- Atlanta, Georgia
- +1 more
2021-10-26
Oct 26, 2021T
Completed
- Relapsed and/or Refractory Multiple Myeloma
- Ixazomib
- +2 more
- Tokyo, JapanTakeda Selected Site
2021-06-03
Jun 3, 2021H
Terminated
- AML
- AML, Adult
- TAK-659
- Ixazomib
- Indianapolis, IndianaIndiana University Melvin and Bren Simon Cancer Center
2022-03-15
Mar 15, 2022P
Active, not recruiting
- Mantle-Cell Lymphoma
- Ixazomib
- Ibrutinib
- Atlanta, Georgia
- +13 more
2022-03-31
Mar 31, 2022M
Completed
- Myeloid Hematologic Malignancy
- Lymphoid Hematologic Malignancy
- Ixazomib
- New York, New YorkMemorial Sloan Kettering Cancer Center
2021-09-03
Sep 3, 2021M
O
Recruiting
- Newly Diagnosed Multiple Myeloma
- Ixazomib
- Lenalidomide
- West Hollywood, CaliforniaJames R Berenson, MD, Inc.
2020-10-23
Oct 23, 2020B
Active, not recruiting
- B Cell Lymphoma
- Lymphoma
- Ixazomib
- +2 more
- Cleveland, Ohio
- +1 more
2022-03-03
Mar 3, 2022W
Recruiting
- Systemic Sclerosis
- +18 more
- Ixazomib
- Scottsdale, ArizonaMayo Clinic in Arizona
2021-04-30
Apr 30, 2021M
Recruiting
- Metastatic Kidney Medullary Carcinoma
- +4 more
- Doxorubicin
- +5 more
- Houston, TexasM D Anderson Cancer Center
2021-07-14
Jul 14, 2021P
Recruiting
- Multiple Myeloma
- Ixazomib
- Lenalidomide
- Beijing, Beijing, ChinaPekingUMCH
2021-11-30
Nov 30, 2021M
Active, not recruiting
- Multiple Myeloma
- Ixazomib
- Beijing, Beijing, China
- +9 more
2021-11-02
Nov 2, 2021F
Recruiting
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma
- Ixazomib
- +3 more
- Badalona, Spain
- +7 more
2021-01-08
Jan 8, 2021M
Withdrawn
- Liposarcoma
- +4 more
- Selinexor
- Ixazomib
- New York, New YorkColumbia University Medical Center
2020-11-24
Nov 24, 2020T
Completed
- Relapsed and/or Refractory Multiple Myeloma
- Ixazomib
- +2 more
- Nagoya, Aichi, Japan
- +20 more
2020-12-18
Dec 18, 2020R
Active, not recruiting
- Lymphoma, T-Cell, Peripheral
- Romidepsin
- Ixazomib
- Chicago, Illinois
- +6 more
2021-01-15
Jan 15, 2021T
Active, not recruiting
- Multiple Myeloma
- Ixazomib
- Odense, DenmarkOdense University Hospital
2021-11-18
Nov 18, 2021W
Active, not recruiting
- Multiple Myeloma
- Ixazomib
- +2 more
- Duarte, California
- +9 more
2022-01-04
Jan 4, 2022